SCHEDULE: RA Capital Entities Form Joint Filing Agreement

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have entered into a joint filing agreement for SEC Schedule 13G/13D filings concerning Corbus Pharmaceuticals Holdings, Inc.

Summary

• A joint filing agreement has been established between RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the 'Filers').
• This agreement allows the Filers to file a single Schedule 13G and/or 13D statement with the SEC regarding common stock of Corbus Pharmaceuticals Holdings, Inc. that they beneficially own.
• The agreement is effective as of September 30, 2026, and can be terminated with one week's prior written notice.
• The filing details the beneficial ownership of 1,914,788 shares of Corbus Pharmaceuticals Holdings, Inc. common stock, representing 9.9% of the class.
• RA Capital Management, L.P. acts as the investment adviser for RA Capital Healthcare Fund, L.P. and may be deemed a beneficial owner of the Fund's securities.
• Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P., and may be deemed beneficial owners of securities held by RA Capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, establishing a joint filing agreement for Schedule 13G/13D without disclosing new material financial or strategic information.

Positives

• Establishes a clear framework for coordinated SEC filings, potentially improving efficiency and transparency for the involved parties.
• The joint filing agreement ensures compliance with SEC regulations for beneficial ownership reporting.

Negatives

• No new financial or strategic information about Corbus Pharmaceuticals Holdings, Inc. is disclosed in this filing.
• The filing does not provide insights into the investment strategy or performance of the RA Capital entities.

Risks

• Potential for regulatory scrutiny if the joint filing agreement is not meticulously adhered to.
• Any changes in the relationship or investment strategies among the Filers could necessitate amendments to the filing agreement and subsequent filings.

Future Outlook

This filing is administrative and does not contain forward-looking statements or guidance regarding Corbus Pharmaceuticals Holdings, Inc.'s future performance.

Management Comments

• The Filers expressly disclaim status as a 'group' for purposes of this Schedule 13G.
• RA Capital disclaims beneficial ownership of securities held by the Fund, as the Fund has divested voting and investment power with more than 61 days' notice.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of reported securities other than for determining obligations under Section 13(d) of the Act.

Industry Context

StockSavvy.ai notes that joint filing agreements are common among investment firms and related entities when accumulating significant stakes in public companies, aiming to streamline reporting obligations under SEC rules.

Related Party Transactions

• RA Capital Management, L.P. serves as the investment adviser for RA Capital Healthcare Fund, L.P.
• RA Capital Healthcare Fund GP, LLC is the general partner of RA Capital Healthcare Fund, L.P.
• RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are controlling persons, is the general partner of RA Capital Management, L.P.

Stakeholder Impact

• Shareholders of Corbus Pharmaceuticals Holdings, Inc. are informed of the coordinated reporting by significant beneficial owners.
• Regulatory bodies will have a consolidated view of the beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock by the Filers.

Next Steps

• The Filers will file a single Schedule 13G and/or 13D statement with the SEC for their beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock.
• The Joint Filing Agreement may be terminated by any Filer with one week's prior written notice.

Key Dates

Keywords

Joint Filing Agreement, Schedule 13G, Schedule 13D, Beneficial Ownership, RA Capital Management, Corbus Pharmaceuticals, SEC Filing